Heptares and Kymab in collaboration to bring new antibodies to market

Heptares Therapeutics, a subsidiary of Japanese drugmaker Sosei Group (TYO Mothers Index: 4565), has entered into a strategic collaboration with UK-based pharma company Kymab, to develop and market novel antibody therapeutics.

These antibodies will target a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology, activating the body’s immune system to produce an immune response targeted at tumor cells.

Immunotherapy drugs have been hailed as having the potential to revolutionize the way cancer is treated and a number of immunotherapy antibody treatments have recently been approved.